Liabilities and Equity in USD of Inhibrx Biosciences, Inc. from Q4 2023 to Q3 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary: Inhibrx Biosciences, Inc. quarterly Liabilities and Equity history and growth rate from Q4 2023 to Q3 2025.
Inhibrx Biosciences, Inc. Liabilities and Equity for the quarter ending September 30, 2025 was $177M, a 20.3% decline year-over-year.

Liabilities and Equity, Quarterly (USD)

Liabilities and Equity, YoY Quarterly Growth (%)

Inhibrx Biosciences, Inc. Quarterly Liabilities and Equity (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q3 2025	$177M	-$45.1M	-20.3%	Sep 30, 2025	10-Q	2025-11-14
Q2 2025	$212M	-$46.3M	-17.9%	Jun 30, 2025	10-Q	2025-08-13
Q1 2025	$243M			Mar 31, 2025	10-Q	2025-05-14
Q4 2024	$181M	-$127M	-41.3%	Dec 31, 2024	10-Q	2025-11-14
Q3 2024	$223M			Sep 30, 2024	10-Q	2024-11-14
Q2 2024	$258M			Jun 30, 2024	10-Q	2024-08-13
Q4 2023	$308M			Dec 31, 2023	10-K	2025-03-17

* An asterisk sign (*) next to the value indicates that the value is likely invalid.